Ubiquitin-specific peptide 22 acts as an oncogene in gastric cancer in a son of sevenless 1-dependent manner

ChitChoon Lim, Jiacheng Xu, Tian‐Yin Chen, Jiaxin Xu, Weifeng Chen, Jianwei Hu, Quan‐Lin Li, Yiqun ZhangCancer 2020 · DOI

Abstract

Our results suggest that USP22 acts as an oncogene in gastric cancer in a SOS1-dependent manner, identifying the USP22/SOS1/RAS axis as a potential therapeutic target in gastric cancer.

Introduction

Gastric cancer remains a significant global health challenge, characterized by high mortality rates and complex molecular drivers. Central to the progression of many cancers is the aberrant activation of the RAS signaling pathway, specifically the RAS/ERK and PI3K/AKT branches, which govern cell proliferation, survival, and migration.

In most malignancies, RAS hyperactivation is driven by direct mutations in the RAS genes. However, gastric cancer presents a biological paradox: while the pathway is frequently hyperactive, direct RAS mutations are remarkably rare. This suggests the existence of alternative upstream mechanisms that force wild-type RAS into a constitutive "on" state. This study investigates the role of USP22 (Ubiquitin-specific peptide 22), a deubiquitinating enzyme, as a potential driver of this activation through the regulation of SOS1 (Son of Sevenless 1).

Clinical Validation and Expression Patterns

To determine the clinical relevance of USP22, researchers utilized immunohistochemical (IHC) staining on a tissue microarray consisting of 88 pairs of primary gastric cancer and adjacent normal tissues. The analysis revealed that USP22 was significantly overexpressed in 78.4% of cancer tissues compared to only 23.9% of normal tissues. These findings were corroborated by external validation using mRNA expression data from The Cancer Genome Atlas (TCGA) database.

USP22 expression in gastric cancer tissues and its clinical correlation.

Statistical analysis showed that high USP22 expression correlated strongly with advanced T stage (tumor depth and size). While survival trends indicated that USP22-negative patients had a higher 5-year survival rate (42.1% vs 30.4%), the difference did not reach statistical significance in this cohort, suggesting the need for larger multi-center studies to confirm its value as a definitive prognostic biomarker.

Functional Role in Tumor Progression

The study employed both gain-of-function and loss-of-function models to assess the impact of USP22 on cellular behavior. The SGC7901 cell line (low baseline USP22) was used for overexpression experiments, while the AGS cell line (high baseline USP22) was used for silencing experiments.

Functional impact of USP22 on gastric cancer cell proliferation and migration.

Functional assays demonstrated that USP22 overexpression significantly accelerated cell proliferation, migration, and invasion. Conversely, silencing USP22 in AGS cells led to a marked reduction in these oncogenic traits. These cellular findings were further validated in vivo using nude mouse xenograft models, where USP22-overexpressing tumors were significantly larger and heavier than controls, while USP22-silenced tumors showed inhibited growth.

The USP22/SOS1/RAS Signaling Axis

The molecular mechanism underlying USP22's oncogenic activity was identified through Chromatin Immunoprecipitation sequencing (ChIP-seq). The data revealed that USP22 induces the upregulation of SOS1, a Guanine Nucleotide Exchange Factor (GEF) that physically activates RAS by promoting the exchange of GDP for GTP.

This discovery explains the "RAS paradox" in gastric cancer: cells do not require mutated RAS if they possess an overabundance of USP22 and SOS1 to keep wild-type RAS constantly active. Western blot analysis confirmed that USP22 levels directly influence the protein levels of SOS1, active RAS, and downstream effectors like p-ERK and p-AKT. Crucially, the study proved that these effects are SOS1-dependent; silencing SOS1 effectively reversed the pro-cancer effects induced by USP22 overexpression.

Conclusion

This research identifies USP22 as a potent oncogene in gastric cancer that drives tumor progression via the SOS1/RAS signaling axis. By bypassing the requirement for direct RAS mutations, the USP22/SOS1/RAS pathway represents a critical vulnerability in gastric cancer. These findings highlight USP22 and SOS1 as promising targets for the development of novel precision therapies aimed at disrupting aberrant RAS signaling.

Summary updated

Abstract

Our results suggest that USP22 acts as an oncogene in gastric cancer in a SOS1-dependent manner, identifying the USP22/SOS1/RAS axis as a potential therapeutic target in gastric cancer.
BibTeX
@inproceedings{lim2020ubiquitin,
  author = {ChitChoon Lim and Jiacheng Xu and Tian‐Yin Chen and Jiaxin Xu and Weifeng Chen and Jianwei Hu and Quan‐Lin Li and Yiqun Zhang},
  title = {{Ubiquitin-specific peptide 22 acts as an oncogene in gastric cancer in a son of sevenless 1-dependent manner}},
  booktitle = {Cancer},
  year = {2020},
  doi = {10.1186/s12935-020-1137-y},
}
Figure